Alzheimer's Disease
Conditions
Interventions
Medication group:Traditional medication
Surgical group :Deep Cervical Lymphatic-Venous Anastomosis,DCLVA
Sponsors
The Second People’s Hospital of Guiyang
Eligibility
Sex/Gender
All
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 50-85 years who met the 2011 NIA-AA diagnostic criteria and were diagnosed with AD; 2. MMSE10-20, CDR-SB 1-3; 3. Disease duration >=1 year; 4. For patients who had been taking AD drugs for a long time, there was no change in treatment plan within 3 months before enrollment; 5. The AD patients were accompanied by a stable and reliable informant (someone who spent at least 8 hours with the participants per week) during the whole study; 6. All enrolled patients were required to complete the required examinations and follow up, and signed the informed consent form (subjects or relatives, caregivers).
Exclusion criteria
Exclusion criteria: 1. Combined with any neurological diseases that may affect cognitive function, including stroke, Parkinson's disease, epilepsy, intracranial tumors or space-occupying lesions, brain trauma, intracranial infection, metabolic encephalopathy, etc. Combined with other causes of dementia, including vascular dementia, hereditary cerebral small vessel disease, vitamin deficiency or any other cause of dementia, etc. 2. A history of a primary psychiatric disorder (schizophrenia, schizoaffective disorder, major depressive disorder or bipolar disorder) other than AD; 3. Patients with severe physical activity, language, vision, hearing, consciousness disorder or disability can not complete the cognitive function assessment; 4. A history of drug or alcohol abuse or dependence; History of malignant tumor, or head and neck radiotherapy or surgery; 5. History of major surgery or severe head or body trauma within 30 days; Patients with other serious life-threatening diseases at the same time and expected survival time less than 2 years; There were contraindications to head MRI examination (including pacemaker/defibrillator, ferromagnetic metal implants, etc.). 6. Preoperative anesthesia evaluation of ASA grade 3 or above, or unable to tolerate deep cervical lymph node venous anastomosis; 7. The following abnormal laboratory tests are present: 8. Serum creatinine exceeds the upper limit of normal value, ALT or AST exceeds 1.5 times the upper limit of normal value, and glomerular filtration rate (eGFR) is less than 60; 9. Bleeding tendency (including but not limited to) : platelet count =35 seconds; He was taking oral warfarin and his INR was >1.7. 10. Oral use of novel oral anticoagulants; 11. Uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >95mmHg); 12. Co-infection with HIV, treponema pallidum, or other infectious diseases considered by researchers to be uncontrolled; Use of another investigational drug or device or participation in another interventional clinical study within 30 days before the date of informed consent; 13. Patients who are pregnant, lactating, likely to become pregnant or plan to become pregnant; 14. Relatives of the investigators (spouse, parents, children or siblings), staff of the research institution or third party organizations, and other persons who may have an interest in the research, and patients who are participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CDR-SB;PET Aß/Tau;Activities of daily living, ADL;Brain atrophy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Neuropsychiatric symptoms, NPI; | — |
Countries
China
Contacts
Public ContactXu Jun,Liu Qing,Wang Cheng
The Second People’s Hospital of Guiyang
Outcome results
None listed